Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Influenza Vaccine Market 

5.1. COVID-19 Landscape: Influenza Vaccine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Influenza Vaccine Market, By Vaccine Type

8.1. Influenza Vaccine Market Revenue and Volume Forecast, by Vaccine Type, 2023-2032

8.1.1. Quadrivalent

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Trivalent

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Influenza Vaccine Market, By Technology

9.1. Influenza Vaccine Market Revenue and Volume Forecast, by Technology, 2023-2032

9.1.1. Egg-based

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Cell culture

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Influenza Vaccine Market, By Age Group 

10.1. Influenza Vaccine Market Revenue and Volume Forecast, by Age Group, 2023-2032

10.1.1. Pediatric

10.1.1.1. Market Revenue and Volume Forecast (2020-2032)

10.1.2. Adult

10.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 11. Global Influenza Vaccine Market, By Route of Administration 

11.1. Influenza Vaccine Market Revenue and Volume Forecast, by Route of Administration, 2023-2032

11.1.1. Injection

11.1.1.1. Market Revenue and Volume Forecast (2020-2032)

11.1.2. Nasal Spray

11.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 12. Global Influenza Vaccine Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.1.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.1.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.1.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.1.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.1.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.1.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.1.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.1.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.1.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.7.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.7.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.8.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.8.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.7.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.7.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.8.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.8.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.7.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.7.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.8.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.8.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.5.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.5.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.5.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.5.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.5.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.5.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

Chapter 13. Company Profiles

13.1. Sanofi Pasteur

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. GlaxoSmithKline plc (GSK)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Seqirus (a CSL Limited Company)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Pfizer Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. AstraZeneca

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. BiondVax Pharmaceuticals Ltd.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Novavax, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Bharat Biotech

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Johnson & Johnson

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. MedImmune, LLC (AstraZeneca)

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms